Summit Therapeutics Inc 2024年度报告

(Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedDecember 31, 2024or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from toCommission file number:001-36866 Summit Therapeutics Inc.(Exact Name of Registrant as Specified in its Charter) 37-1979717 (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☒No☐ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements forthe past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company”in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal controlover financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued itsaudit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filingreflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received byany of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No☒ The aggregate market value of the voting common stock held by non-affiliates based on the closing stock price on June 30, 2024, was $827.3million. Forpurposes of this computation only, all executive officers and directors have been deemed affiliates. The number of outstanding shares of the registrant’s common stock, par value $0.01 per share, as of February18, 2025 was737,679,704. Documents Incorporated by ReferencePortions of the registrant’s definitive proxy statement relating to the registrant’s 2025 annual meeting of stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K. The registrant’s definitive proxy statement will be filed with the U.S. Securities and ExchangeCommission within 120 days after the end of the fiscal year to which this report relates. TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking StatementsPART I Item1.Business1Item1A.Risk Factors27Item1B.Unresolved Staff Comments62Item 1C.Cybersecurity62Item2.Properties63Item3.Legal Proceedings63Item4.Mine Safety Disclosures63PART IIItem5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities64Item6.[Reserved]65Item7.Management’s Discussion and Analysis of Financial Condition and Results of Operations65Item7A.Quantitative and Qualitative Disclosures About Market Risk77Item8.Financial Statements and Supplementary Data78Item9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure78Item9A.Controls and Procedures78Item9B.Other Information79Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections79PART IIIItem10.Directors, Executive Officers, and Corporate Governance79Item11.Executive Compensation79Item12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters79Item13.Certain Relationships and Related Transactions, and Director Independence79Item14.Principal Accounting Fees and Services79PART IVItem15.Exhibits, Financial Sta